Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/22/2025 | $21.00 | Buy | Craig Hallum |
| 3/17/2025 | $20.00 | Buy | H.C. Wainwright |
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
SC 13D - ACTUATE THERAPEUTICS, INC. (0001652935) (Subject)
HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati
Craig Hallum initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $21.00
H.C. Wainwright initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00
8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
S-8 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
10-Q - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
Phase 2 (Actuate-1801 Part 3B) trial topline results meet primary endpoint of improved survival in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)Oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting to highlight statistically significant improvement in median overall survival and 1-year survival rate in patients treated with the combination of elraglusib and gemcitabine/nab-paclitaxel (GnP) compared to GnP aloneCompany to host KOL event on May 31, 2025, to review data presented CHICAGO and FORT WORTH, Texas, May 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clin
Fireside discussion to explore clinical impact of the topline Phase 2 data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) to be presented at ASCOIn-person event and virtual webcast to be held on Saturday, May 31, 2025, at 6:30 pm CDT CHICAGO and FORT WORTH, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it will host an in-person key opinion leader (KOL) event, during the 2025 American
Topline data shows statistically significant improvement in overall survival in elraglusib plus GnP combination arm versus GnP control armElraglusib/GnP combination arm demonstrated substantial improvement in median overall survival since the last data analysisClinical trial meets primary endpoint for overall survival and confirms significant 1-year survival rateElraglusib/GnP combination arm demonstrated a favorable risk-benefit profileTopline dataset to be presented in an oral presentation at the upcoming ASCO Annual Meeting Company plans to work with regulators to expeditiously bring elraglusib to commercialization CHICAGO and FORT WORTH, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Actua